This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Vladimir Hachinski, MD, FRCP(C)
Division of Cerebrovascular Research University Hospital PO Box 5339, Postal Station A London, Ontario, Canada N6A 5A5

Arch Neurol. 1988;45(1):15.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Nadeau contributes a fresh viewpoint to decision making regarding levodopa therapy. Although the concept of "risk aversion" is relevant and quantifiable, it does not take due account of the influence that the physician and others may have on the patient's perception of risk, nor of the fact that "risk aversion" may be conditioned by depression and cognitive impairment, two common accompaniments of Parkinson's disease.

The claim that risk aversion, or, indeed, any aspect of clinical decision analysis¹ can definitely settle controversies is, to say the least, controversial. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?